Working… Menu
Trial record 79 of 1439 for:    prostate cancer AND radiation

Low Dose Hemi-body Radiation For Recurrent Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03196778
Recruitment Status : Not yet recruiting
First Posted : June 23, 2017
Last Update Posted : June 26, 2017
McMaster University
Northern Ontario School of Medicine
Information provided by (Responsible Party):
Ian Dayes, Juravinski Cancer Center

Brief Summary:
Older studies in animals and humans have shown cancer responses to very low doses of whole-body or hemi-body radiation. To study the effects of low doses of radiation in patients with recurrent prostate cancer, investigators will enroll up to 21 patients for 10 fractions of low dose radiation, delivered over 5 weeks. Participants will be followed on study for 12 months, capturing PSA, CBC, QoL and blood samples for immunological analysis.

Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: Low Dose Radiotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer
Estimated Study Start Date : July 2017
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Intervention Details:
  • Radiation: Low Dose Radiotherapy
    Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks

Primary Outcome Measures :
  1. PSA response [ Time Frame: Within 12 months of study treatment ]
    Proportion of patients with a reduction of PSA levels by at least 50%

Secondary Outcome Measures :
  1. Immunological changes [ Time Frame: Within 12 months of study treatment ]
    Levels of CD8+ and CD16+ cells, cytokine levels

  2. Adverse Events [ Time Frame: Within 12 months of study treatment ]

  3. Quality of Life [ Time Frame: Within 12 months of study treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A confirmed diagnosis of prostate cancer.
  • Having undergone prior prostate surgery or radiotherapy or both.
  • Evidence of recurrence of the disease as demonstrated by rising PSA levels. Patients are eligible if on androgen blockade or hormone naïve.

Exclusion Criteria:

  • Prior treatment with chemotherapy and/or abiraterone and/or enzalutamide and/or radium-223.
  • Receiving treatment with immunosuppressive medications.
  • Platelet count below 50,000/µl (50 x 109/l) or leukocyte count below 3,000/µl (3 x 109/l) or granulocyte count below 2,000/µl (2 x 109/l).
  • Other medical conditions or co-morbidities which, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.
  • Language difficulties which may hinder the patient's ability to complete the trial.
  • Inability of the potential participant to provide consent.
  • Lack of independence in daily living activities and any other conditions which, in the opinion of the Investigator, will hinder the participant's ability to participate and complete the study obligations.

Layout table for additonal information
Responsible Party: Ian Dayes, Assoc. Professor, Dept of Oncology, Juravinski Cancer Center Identifier: NCT03196778     History of Changes
Other Study ID Numbers: Prostate Hemi-body Irradiation
First Posted: June 23, 2017    Key Record Dates
Last Update Posted: June 26, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No plan to share IPD. Results to be reported as aggregate outcomes for the group.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases